Company profile for Zumutor Biologics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Zumutor is a leading Immuno-Oncology company in the space of targeted NK cell therapeutics. Our proprietary Human Antibody platform INABLR ™ is the genesis to our wholly owned, first-in-class therapeutic antibodies which target innate immunity and regulate the tumor micro environment. Formed in 2013, we are headquartered at CIC Cambridge Campus, 1 Broadway, Cambridge, MA, USA and an ISO 9001:2015 laboratory in Bangalore, In...
Zumutor is a leading Immuno-Oncology company in the space of targeted NK cell therapeutics. Our proprietary Human Antibody platform INABLR ™ is the genesis to our wholly owned, first-in-class therapeutic antibodies which target innate immunity and regulate the tumor micro environment. Formed in 2013, we are headquartered at CIC Cambridge Campus, 1 Broadway, Cambridge, MA, USA and an ISO 9001:2015 laboratory in Bangalore, India. Our key drivers to success include a platform approach to novel therapeutics, an experienced Antibody engineering team, global advisors and investors.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
CIC Cambridge Campus 1 Broadway, Cambridge MA 02142
Telephone
Telephone
+91 80 69121400
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Natural Product Expo West

Natural Product Expo West

Not Confirmed

envelop Contact Supplier

Natural Product Expo West

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/zumutor-biologics-announces-dosing-of-first-patient-with-zm008-a-first-in-class-anti-llt1-antibody-302170537.html

PR NEWSWIRE
12 Jun 2024

https://www.prnewswire.com/news-releases/zumutor-biologics-inc-announces-fda-clearance-of-ind-application-of-zm008-a-novel-monoclonal-antibody-drug-against-multiple-solid-cancers-301898699.html

PR NEWSWIRE
11 Aug 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty